Advancements in mCRPC: Perspectives From the PEACE III Trial
Alicia Morgans, MD, MPH, discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved radiographic progression-free survival and overall survival compared to enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had bone metastases and limited prior treatment exposure, establishing this combination as a new standard of care when used with mandatory bone protective agents.
EP. 1: Insights From the PEACE III Trial
June 30th 2025An expert discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved radiographic progression-free survival and overall survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had bone metastases and limited prior treatment exposure.
Watch
EP. 2: Bone-Protecting Agents in mCRPC
June 30th 2025An expert discusses how the PEACE III trial demonstrated that combining radium-223 with enzalutamide significantly improved radiographic progression-free survival and overall survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer (mCRPC) who had bone metastases and limited prior treatment exposure.
Watch
EP. 3: Scanning Methods and Treatment Selection
July 11th 2025An expert discusses how CT scans and bone scans remain the standard imaging approach for most patients with metastatic castration-resistant prostate cancer (mCRPC), whereas prostate-specific membrane antigen (PSMA) PET scans are primarily reserved for selecting patients for specific treatments such as lutetium Lu 177 vipivotide tetraxetan (Pluvicto), though they may offer better sensitivity for detecting soft tissue disease in radium-223 candidates.
Watch
EP. 4: Sequencing Strategies in mCRPC
July 11th 2025An expert discusses how the PEACE III combination of radium-223 and enzalutamide represents an effective treatment option for the limited population of patients who reach first-line metastatic castration-resistant prostate cancer (mCRPC) without prior androgen receptor pathway inhibitor exposure, while other combinations such as radium-223 plus olaparib showed mixed results with concerning toxicity profiles.
Watch
